Andrew John Fisher
Ranked 10 by citations to CLAD papers over ten years: 20 papers in the corpus, 1,441 citations. A bibliometric entry, not a quality judgement.
As of . Primary source: ORCID record.
Summary
Andrew John Fisher appears as an author of 20 papers (3.23 fractional) in the OpenAlex corpus of CLAD-related articles published from 2016-10-11 to 2026-10-10 (retrieved 2026-10-10). Those papers have been cited 1,441 times in total (whole counting), which places this author at rank 10 among 8,698 author profiles after merging duplicate OpenAlex profiles. 11 of the papers list the author in the first or last position. Without the two 2019 ISHLT consensus papers the count is 489 citations (rank 40); the whole-count rank is strongly influenced by a consensus paper. Affiliation: Newcastle University, Newcastle upon Tyne (GB). Basis: ORCID record, employment entries without an end date (self-asserted, may be out of date). The corpus includes papers that only partly concern CLAD, and the counts describe publication and citation volume only. Linked papers are the author's most-cited papers matching CLAD terms in the title where possible.
Ranking method and caveats
Methodology for the researcher ranking
- Query: OpenAlex works of type article or review whose title or abstract contains "chronic lung allograft dysfunction" or "restrictive allograft syndrome", or "bronchiolitis obliterans" together with lung transplant terms. Retracted works and meeting-abstract supplements are removed.
- Window and date: works published 2016-10-11 to 2026-10-10; counts retrieved 2026-10-10 (2,461 works, 8,698 author profiles after merging).
- Counting: the rank is by total citations of the author's papers (whole counting). Fractional counts, first or last author papers and counts without the two 2019 ISHLT consensus papers are shown on each record.
- Identity: authors are identified by OpenAlex author identifier and ORCID. Duplicate profiles were merged by identical ORCID, or by compatible name plus shared institution. Only the top 30 entries were checked by hand.
- Rising researchers: a separate numbered list ordered by citations in the 5 years from 2021-10-11, for authors whose first paper in the corpus is dated 2019 or later and who have at least 5 papers in that window. It is a proxy, not a measure of career stage.
- Caveats: the corpus includes papers only partly about CLAD; consensus papers inflate some totals; recent papers are under-cited; author identifiers can be wrong; citations measure attention, not quality or clinical skill.
Details
- affiliation
- Newcastle University, Newcastle upon Tyne (GB)
- citation rank 10y
- 10 of 8,698 author profiles (top 100 listed)
- papers 10y
- 20
- fractional papers 10y
- 3.23
- citations 10y
- 1441
- fractional citations 10y
- 136.8
- lead author papers 10y
- 11
- citations excluding two ishlt2019consensus papers
- 489
- rank excluding two ishlt2019consensus papers
- 40
- ranking retrieved
- 2026-10-10
- orcid
- 0000-0003-4822-7223
- openalex author id
- A5077353591
- merged open alex profiles
- 2
- affiliation basis
- ORCID record, employment entries without an end date (self-asserted, may be out of date)
Sources and links
- ORCID record (primary)
- OpenAlex author profile (ranking source)
- Most-cited CLAD paper in corpus: Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment―A consensus report from the Pulmonary Council of the ISHLT (The Journal of Heart and Lung Transplantation, 2019); 952 citations; DOI 10.1016/j.healun.2019.03.009
- Most-cited CLAD paper in corpus: Immune processes in the pathogenesis of chronic lung allograft dysfunction: identifying the missing pieces of the puzzle (European Respiratory Review, 2022); 45 citations; DOI 10.1183/16000617.0060-2022
- Most-cited CLAD paper in corpus: Effector immune cells in chronic lung allograft dysfunction: A systematic review (Immunology, 2022); 26 citations; DOI 10.1111/imm.13458
- Most-cited CLAD paper in corpus: Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK) (BMJ Open Respiratory Research, 2024); 15 citations; DOI 10.1136/bmjresp-2023-001995
- Most-cited CLAD paper in corpus: Lymphocyte Depleting and Modulating Therapies for Chronic Lung Allograft Dysfunction (Pharmacological Reviews, 2023); 12 citations; DOI 10.1124/pharmrev.123.000834
Related
Links from this record
Known gaps in this record
- role or job title
- centre membership relation (not asserted)
- funding and conflicts of interest
- rank depends largely on one 2019 consensus paper; see counts excluding consensus papers
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.